Atrium Therapeutics Executives Flood Shareholdings with Massive RSU‑Option Purchases, Signaling Strong Confidence in RNA‑Based Cardiac Pipeline
Insider buying spree at Atrium Therapeutics shows top execs betting on RNA‑based heart‑disease pipeline, hinting at future upside and strategic alignment.
3 minutes to read